Blacks With Glaucoma at Higher Risk for Visual Field Loss
TUESDAY, July 26, 2022 -- Compared with non-Hispanic Whites, Blacks have higher risks for primary open-angle glaucoma (POAG) with early and advanced visual field (VF) loss, according to a study published in the July issue of Translational Vision... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - July 26, 2022 Category: Pharmaceuticals Source Type: news
Black Patients More Likely to Lose Vision After Glaucoma Diagnosis
TUESDAY, July 26, 2022 -- Black patients should start screening early for glaucoma, because they have a high risk of vision loss caused by elevated pressure levels inside the eye, researchers say.
A team from New York Eye and Ear Infirmary of Mount... (Source: Drugs.com - Daily MedNews)
Source: Drugs.com - Daily MedNews - July 26, 2022 Category: General Medicine Source Type: news
Black People More Likely to Lose Eyesight From Glaucoma Black People More Likely to Lose Eyesight From Glaucoma
Glaucoma steals the vision of Black people more often than non-Hispanic White people.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - July 25, 2022 Category: Consumer Health News Tags: Ophthalmology News Source Type: news
AbbVie and iSTAR Medical Announce Strategic Alliance for the Treatment of Glaucoma
Alliance will provide opportunity for AbbVie to further expand its diverse eye care portfolio and provide additional treatment options for glaucoma patients
Collaboration further supports the role of MINIject® in the treatment of glaucoma and accele... Devices, Ophthalmology AbbVie, iSTAR Medical, MINIject, glaucoma (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - July 20, 2022 Category: Pharmaceuticals Source Type: news
Blood Pressure, Blood Pressure Medications, and Glaucoma Blood Pressure, Blood Pressure Medications, and Glaucoma
Dr Shuchi Patel and Dr Ruth Williams discuss the relationship between blood pressure and glaucoma, including some simple but useful clinical pearls.Medscape Ophthalmology (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - July 18, 2022 Category: Consumer Health News Tags: Ophthalmology Viewpoint Source Type: news
Glaucoma Not Linked to Change in Cognitive Function
WEDNESDAY, July 6, 2022 -- Prevalent and incident glaucoma seem not to be associated with changes in cognitive function, according to a study published online June 22 in the Journal of the American Geriatrics Society.
Ajay Kolli, M.D., M.P.H., from... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - July 6, 2022 Category: Pharmaceuticals Source Type: news
ADRIAN MONTI: New implant to treat glaucoma - and get your cataracts done at the same time!
Roger Pledge, 76, from Colchester, Essex, was the first in the UK to have a new type of implant fitted in both eyes to combat it, as he tells Adrian Monti. (Source: the Mail online | Health)
Source: the Mail online | Health - July 5, 2022 Category: Consumer Health News Source Type: news
One in five Britons don't know what a cataract or glaucoma is, poll finds
At least 10% of people will suffer age-related eye problems such as cataracts or glaucoma, but the survey of 2,000 Britons commissioned by the charity Guide Dogs shows a lack of awareness among the general public. (Source: the Mail online | Health)
Source: the Mail online | Health - June 25, 2022 Category: Consumer Health News Source Type: news
Janssen Presents Updated Data at EHA for Teclistamab in Patients with Relapsed or Refractory Multiple Myeloma
June 10, 2022 (VIENNA) – The Janssen Pharmaceutical Companies of Johnson & Johnson announced updated efficacy and safety results from the teclistamab cohort of the Phase 1b TriMM-2 study (NCT04108195). Teclistamab, an investigational, off-the-shelf, T-cell redirecting bispecific antibody targeting B-cell maturation antigen (BCMA) is being studied in combination with DARZALEX FASPRO® (daratumumab and hyaluronidase-fihj) in patients with relapsed or refractory multiple myeloma (RRMM) who have received three or more prior lines of therapy.1 Patients in the study, including a high proportion with prior anti-CD38 exposur...
Source: Johnson and Johnson - June 10, 2022 Category: Pharmaceuticals Tags: Innovation Source Type: news
Janssen Presents Updated Results Evaluating First-in-Class GPRC5D Bispecific Antibody Talquetamab in Heavily Pretreated Patients with Multiple Myeloma
June 10, 2022 (VIENNA) – The Janssen Pharmaceutical Companies of Johnson & Johnson announced updated results from the Phase 1 MonumenTAL-1 first-in-human dose-escalation study of talquetamab (NCT03399799), an investigational, off-the-shelf, T cell redirecting bispecific antibody targeting both GPRC5D, a novel multiple myeloma target, and CD3 on T cells.1 Results from the study showed encouraging responses in heavily pretreated patients with relapsed or refractory multiple myeloma (RRMM) who received talquetamab at the recommended subcutaneous Phase 2 dose (RP2D) administered weekly (QW) or every two weeks (Q2W).2 The...
Source: Johnson and Johnson - June 10, 2022 Category: Pharmaceuticals Tags: Innovation Source Type: news
Evidence Lacking for Glaucoma, Impaired Vision Screening Evidence Lacking for Glaucoma, Impaired Vision Screening
Task force calls for more research to determine value of screening in primary care.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - June 2, 2022 Category: Consumer Health News Tags: Ophthalmology News Source Type: news
Janssen to Highlight Science, Innovation and Advances in Robust Oncology Portfolio and Pipeline Through More Than 60 Data Presentations at ASCO and EHA
RARITAN, N.J., May 31, 2022 — The Janssen Pharmaceutical Companies of Johnson & Johnson announced today that new research and data from its robust oncology portfolio and pipeline of investigational therapies will be presented at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting, taking place June 3-7 in Chicago, and the European Hematology Association (EHA) 2022 Congress taking place in Vienna, Austria, June 9-12. More than 60 presentations from company-sponsored studies across the two congresses, including 14 oral presentations, will feature new data and updates for both approved and investigation...
Source: Johnson and Johnson - May 31, 2022 Category: Pharmaceuticals Source Type: news
Glaucoma patient pathways guidance
The College of Optometrists and The Royal College of Ophthalmologists have developed guidance in response to the National Institute for Health and Care Excellence NG81 Glaucoma: diagnosis and management guidance to enable high-quality care for glaucoma patients, using the wide range of professional skills available. (Source: NHS Networks)
Source: NHS Networks - May 26, 2022 Category: UK Health Source Type: news
USPSTF: Evidence Lacking for Glaucoma Screening in Adults
TUESDAY, May 24, 2022 -- The U.S. Preventive Service Task Force (USPSTF) concludes that the evidence is currently insufficient to assess the balance of benefits and harms for screening for glaucoma in asymptomatic adults and for impaired visual... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - May 24, 2022 Category: Pharmaceuticals Source Type: news
The PreserFlo MicroShunt: A Conversation With Dr Ike Ahmed The PreserFlo MicroShunt: A Conversation With Dr Ike Ahmed
Dr Patel interviews Iqbal"Ike" K. Ahmed, MD, about the PreserFlo MicroShunt, an 8-mm-long tube that is inserted into the eye to help lower eye pressure in glaucoma.Medscape Ophthalmology (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - May 19, 2022 Category: Consumer Health News Tags: Ophthalmology Viewpoint Source Type: news
